RemeGen Co., Ltd. (9995.HK)
HKD 41.4
(8.8%)
HKD 41.4
(8.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.09 Billion CNY | 100.88% |
| 2022 | 1.04 Billion CNY | 46.03% |
| 2021 | 712.78 Million CNY | 36.27% |
| 2020 | 523.07 Million CNY | -43.22% |
| 2019 | 921.28 Million CNY | -10.49% |
| 2018 | 1.02 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.4 Billion CNY | 14.78% |
| 2024 Q2 | 3.08 Billion CNY | 28.74% |
| 2023 Q2 | 1.53 Billion CNY | 53.95% |
| 2023 FY | 2.09 Billion CNY | 100.88% |
| 2023 Q1 | 997.69 Million CNY | -4.15% |
| 2023 Q4 | 2.09 Billion CNY | 34.2% |
| 2023 Q3 | 1.55 Billion CNY | 1.44% |
| 2022 Q2 | 662.61 Million CNY | -2.11% |
| 2022 FY | 1.04 Billion CNY | 46.03% |
| 2022 Q4 | 1.04 Billion CNY | 47.95% |
| 2022 Q3 | 703.54 Million CNY | 6.18% |
| 2022 Q1 | 676.89 Million CNY | -5.04% |
| 2021 FY | 712.78 Million CNY | 36.27% |
| 2021 Q2 | 555.01 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 Q4 | 712.78 Million CNY | 0.0% |
| 2020 Q2 | 829 Million CNY | 12.13% |
| 2020 FY | 523.07 Million CNY | -43.22% |
| 2020 Q4 | 523.07 Million CNY | 0.0% |
| 2020 Q3 | 523.07 Million CNY | -36.9% |
| 2020 Q1 | 739.31 Million CNY | -19.75% |
| 2019 Q3 | 921.28 Million CNY | 0.0% |
| 2019 FY | 921.28 Million CNY | -10.49% |
| 2019 Q4 | 921.28 Million CNY | 0.0% |
| 2018 FY | 1.02 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -1268.277% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 70.375% |